RevMedx receives CE Mark for XGAUZE® Self-Expanding Gauze

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Today RevMedx, Inc., a global leader in innovative devices that control severe bleeding, today announced it has received CE (Conformité Européenne) Mark Certification for the XGAUZE® Self-Expanding Gauze (wound dressing) in Europe. XGAUZE, a Class I sterile multi-layer wound dressing, contains an embedded layer of compressed cellulose sponges that expand upon contact with blood or fluid.

XGAUZE is standard issue in selected US Armed Forces medical kits and has several hundred documented treatments since its release in 2015. Using expanding sponge technology similar to RevMedx’s XSTAT injectable device, compressed sponges embedded in XGAUZE rapidly absorb blood and expand to ten times their original size. One expanded XGAUZE fills about the same volume as three standard gauze dressings. XGAUZE may provide significant advantages for wound-packing and treatment of certain types of traumatic injuries seen in pre-hospital settings.

Andrew Barofsky, President and CEO of RevMedx, Inc., stated, “CE Mark on our XGAUZE product now makes our entire portfolio available to emergency responders and surgeons in the European Union and around the world. This certification clearly indicates that XGAUZE and our supporting quality system have met the essential requirements for product safety, performance and usability, in compliance with rigorous requirements set by the EU’s Medical Device Directive (MDD).”

For victims of violence or accidents, early control of severe bleeding may prevent shock and may be life-saving. The United States Army Institute of Surgical Research reports that 30 to 40 percent of civilian deaths by traumatic injury are the result of hemorrhaging; of those deaths, 33 to 56 percent occur before the patient reaches an emergency care facility.



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.